Clinical Trial Update: Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a natural killer cell therapy combined with a PD-1 antibody as second-line treatment for advanced driver mutation-negative non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Natural Killer (NK) cell therapy
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED